A 7-year-old boy is brought to the child psychiatry clinic by his mother with complaints of inattention and hyperactivity for the past 18 months. The teacher reports that he frequently interrupts classmates, cannot sit still during lessons, and loses his pencils and homework regularly. At home, he fidgets constantly, talks excessively, and struggles to follow multi-step instructions. His mother denies any seizures, head injury, or developmental delay. Physical examination is unremarkable. Intelligence testing shows average cognitive ability. Which of the following is the MOST appropriate first-line pharmacological intervention for this child?

Explanation

## Diagnosis and First-Line Management **Key Point:** This child meets DSM-5 criteria for ADHD, Combined Presentation (symptoms of inattention, hyperactivity, and impulsivity present for >6 months, onset before age 12, functional impairment across settings). ### First-Line Pharmacotherapy for ADHD **High-Yield:** Stimulant medications (methylphenidate and amphetamine-based compounds) are the gold standard first-line agents for ADHD in children and adolescents. | Agent | Class | Onset | Duration | First-Line? | |-------|-------|-------|----------|-------------| | Methylphenidate | Stimulant (psychostimulant) | 30–60 min | 3–4 hrs (IR); 8–12 hrs (ER) | **Yes** | | Amphetamine | Stimulant | 30–60 min | 4–6 hrs (IR); 8–12 hrs (ER) | **Yes** | | Atomoxetine | Non-stimulant (SNRI) | 2–4 weeks | 24 hrs | Second-line | | Guanfacine | Alpha-2 agonist | 1–3 weeks | 12–16 hrs | Second-line | | Sertraline | SSRI | 2–4 weeks | 24 hrs | Not indicated | ### Mechanism of Action **Clinical Pearl:** Methylphenidate blocks reuptake of dopamine and norepinephrine in the prefrontal cortex, enhancing executive function, attention, and impulse control. It has the fastest onset and most robust evidence base in pediatric ADHD. ### Typical Dosing - **Methylphenidate:** Start 5 mg once or twice daily; titrate by 5–10 mg weekly; usual range 10–60 mg/day in divided doses (IR) or 20–60 mg/day (ER formulations). - Baseline vital signs and cardiac history must be assessed before initiation. **Key Point:** Non-stimulants (atomoxetine, guanfacine) are reserved for: - Inadequate response to stimulants - Stimulant intolerance or adverse effects - Comorbid tics or Tourette syndrome (relative contraindication to stimulants) - History of substance abuse in family ### Pre-Treatment Assessment 1. Detailed psychiatric and medical history 2. Vital signs and weight 3. Cardiac examination (rule out structural disease, arrhythmia) 4. ECG if family history of sudden cardiac death or personal cardiac symptoms 5. Baseline rating scales (Conners, VANDERBILT) **Warning:** SSRIs (like sertraline) are not indicated for ADHD alone; they are used for comorbid anxiety or depression. [cite:DSM-5 ADHD Criteria; Harrison 21e Ch 460]